Subscribe to the iGaming newsletter 7th August 2018 | By Stephen Carter Topics: Casino & games Finance Sports betting Bingo Poker Tags: Card Rooms and Poker Online Gambling AddThis Sharing ButtonsShare to LinkedInLinkedInShare to FacebookFacebookShare to TwitterTwitter iGaming Dashboard – August 2018 H2 Gambling Capital and iGaming Business are pleased to bring you the August 2018 iGaming Dashboard.The iGaming Dashboard is your monthly overview of the igaming sector in numbers and enables you to follow the evolution of the igaming sector.The numbers have recently been updated to include April 2018 IMF GDP forecasts, an extension of the date range to 2023 and US sports betting.We have also recently added the pre-match vs. in-play split for global sports betting GGR.Click on the different years to see how total global gambling gross win for igaming will evolve between now and 2023, geographical breakdowns provide you with an overview of revenue levels for key regions around the world.The vertical breakdown shows how much different product segments generate and the levels they are set to grow to.The term “white market” is used to describe taxed or fully legitimate markets, including the UK and any other that is in transition.We have removed all unconfirmed forecast igaming activity — mostly five to six US states, including the poker market in California — from our projections due to uncertainty over the timing of future market developments.H2 Gambling Capital is the gambling industry’s leading consulting, market intelligence and data team. The company has a track record of 15 years focused on the global gambling industry, its projections have been influential in shaping legislators’ and investors’ views of the gambling sector across the globe. Projections now extend to 2023 and include post-PASPA US sports betting Bingo Email Address
Staco Insurance Plc (STACO.ng) listed on the Nigerian Stock Exchange under the Insurance sector has released it’s 2012 annual report.For more information about Staco Insurance Plc (STACO.ng) reports, abridged reports, interim earnings results and earnings presentations, visit the Staco Insurance Plc (STACO.ng) company page on AfricanFinancials.Document: Staco Insurance Plc (STACO.ng) 2012 annual report.Company ProfileStaco Insurance Plc is an insurance company in Nigeria licensed to cover non-life insurance for fire, general accident, motor vehicle, oil and gas, marine, aviation, bond and engineering. Other insurance products cover fidelity guarantees, professional indemnity, goods-in-transit, employer liability, burglary, public liability and group/personal accident as well as transportation insurance which includes motor, marine hull and cargo and aviation insurance. Fire and bond insurance products cover fire and special perils, homeowner/holder, all-risks, engineering and bond insurance. Customised insurance products cover motor insurance, personal protection and homeowners insurance. Staco Insurance Plc has business interests in Sierra Leone offering life and non-life insurance products to individuals and corporate customers. Formerly known as Standard Trust Assurance Plc, the company changed its name to Staco Insurance Plc in 2006. Its head office is in Lagos, Nigeria. Staco Insurance Plc is listed on the Nigerian Stock Exchange
Architectural Design: CopyHouses, House Interiors, Sustainability•Mengwi, Indonesia Houses “COPY” Projects Alexis Dornier Save this picture!© KIE+ 47Curated by María Francisca González Share Indonesia Alexis Dornier Architectural Design and Interior: Photographs: KIE, Akhil Hari Haus Flora / Alexis Dornier 2019 Area: 717 m² Year Completion year of this architecture project Architects: Alexis Dornier Area Area of this architecture project Construction:Bali ConstructionLandscape:Anton Joel ClarkInterior Design:Alexis DornierCity:MengwiCountry:IndonesiaMore SpecsLess SpecsSave this picture!© Akhil HariRecommended ProductsWindowsLibartVertical Retracting Doors & WindowsWindowsVEKAWindows – SOFTLINE 82 ADDoorsECLISSESliding Pocket Door – ECLISSE LuceWoodParklex International S.L.Wood cladding – FacadeText description provided by the architects. This 4 bedroom bungalow is submerged into it’s surrounding – the picturesque landscape with rice fields, coconut and palm trees of Bali sets the scene for an understated architecture with surprise. The family home consists of rooms that are separated by greenery and lush foliage. Building elements such as pillars, windows, and walls become visually entangled with trees and bushes, fountains and sculptures – and blend into one memorable event.Save this picture!© Akhil HariSave this picture!Roof PlanSave this picture!© KIEMaterials are chosen so they would amplify this submersion. Natural green stone tiles become the predominant material that pronounces the volumes. Inside surfaces are clad in wood, structural elements in white and floors tiled in natural stone as well.Save this picture!© KIEWith the diagram of a village in mind, rooms were planned to be separated by voids to provide both privacy and a sense of community in one floor plan. Rooms appear more like studios, and their interiors juxtapose the cold facade materials with warm wooden textured backdrops.Save this picture!© KIESave this picture!Section 01Save this picture!Section 03Save this picture!© KIEThe voids hold greenery, and rooms connect with elevated pathways. In the choreography’s heart one finds the kitchen. From here the pathways disperse into all directions. A centrally located flight of stairs connects to the new datum above – the composition creates a series of courtyards. When discovering the rooms, there is constant interplay of interior and exterior spaces.Save this picture!© KIEMaking use of their passive cooling attributes, trees become the conceptual center pieces, and their branches and leaves filter light into the spaces below. The pool and sun decks are situated on top of the living room and bedrooms, and provide views onto the lush surrounding rice paddies and constitute a new datum. The 271 m2 roof provides enough space for solar panels, a vegetable garden and a spacious area for events underneath the stars. Save this picture!© KIETraditional ‘Gladak’ grass roofed structures stand on top, taking any attention off the main building. This was an attempt to produce timeless reductive architecture, to be crowned by simple grass roof structures providing shade and resting areas. They become the remarkable aspect of the design draw the silhouette against the sky. Save this picture!© KIEProject gallerySee allShow lessPhutthamonthon-Y House / Archimontage Design Fields SophisticatedSelected ProjectsHouse 2 – Counter City / AliceSelected Projects Share ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/947031/haus-flora-alexis-dornier Clipboard Haus Flora / Alexis DornierSave this projectSaveHaus Flora / Alexis Dornier Photographs “COPY” ArchDaily ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/947031/haus-flora-alexis-dornier Clipboard Year: CopyAbout this officeAlexis DornierOfficeFollowProductsWoodStone#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesInterior DesignResidential InteriorsHouse InteriorsSustainabilityOn FacebookMengwiIndonesiaPublished on September 06, 2020Cite: “Haus Flora / Alexis Dornier” 06 Sep 2020. ArchDaily. Accessed 10 Jun 2021.
JK Rowling and Richard Curtis donate items for Book Aid auction 33 total views, 2 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis Handwritten pieces by some of Britain’s leading authors and illustrators are to be auctioned for Book Aid International by Bloomsbury Auctions on Tuesday 21st February.Over 30 household names including JK Rowling, Dick King-Smith, Joanna Lumley, Joanna Trollope, William Boyd, David Mitchell, Colin Dexter, Louis Theroux, Lynne Truss, Tracey Emin and Sir Bob Geldof have all contributed original, signed pieces to be auctioned. The proceeds will help Book Aid International get books for schools, libraries, hospitals, universities and refugee camps across Africa.Book Aid International works to make sure that the most disadvantaged people in Africa have access to books and information – from young children learning to read, to doctors treating HIV/AIDS. Over half a million books are provided each year, with additional support for public libraries and local publishing.Many of the authors donating their work will be present at the auction, which will be hosted by Jeremy Paxman and held at 7.30pm on Tuesday 21st February at Bloomsbury Auctions, Bloomsbury House, 24 Maddox Street, London W1S 1PP. Howard Lake | 8 February 2006 | News Tagged with: Celebrity Events AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving.
27 leading food and agriculture associations have sent a letter communicating growing concerns over the rapid deterioration of the U.S.-Mexico trade relationship to Agriculture Secretary Thomas Vilsack and U.S. Trade Representative Katherine Tai. The letter calls attention to alarming recent developments with regard to food and agriculture trade relationship with Mexico and urges action to address these challenges.Together, the group of associations represent much of the food and agriculture sector that is responsible for roughly one-fifth of the country’s economic activity, directly supporting over 23 million jobs – constituting nearly 15 percent of total U.S. employment. Signers include the American Farm Bureau Federation, the American Soybean Association, Corn Refiners Association, International Dairy Foods Association, North American Meat Institute, National Grain & Feed Association, and the U.S. Dairy Export Council.The letter reads:“Mexico is one of America’s most important food and agriculture trade partners. NAFTA has yielded strong benefits to both countries and the U.S.-Mexico-Canada Agreement (USMCA) promises to build upon those gains. Yet, the food and agriculture trade relationship with Mexico has declined markedly, a trend USMCA’s implementation has not reversed. We respectfully urge your attention to this important but quickly deteriorating trade relationship.”Leading concerns highlighted by the group include a ban on glyphosate and genetically modified corn, increased obstacles to dairy trade, an organic export certification requirement, a state-sponsored campaign disparaging corn sweeteners from the U.S., a cessation of review and approval of biotechnology applications, implications from meat industry market access and geographical indications, a potato export ban, and a new front-of-pack labeling regulation. These issues, along with a high number of investigations on Mexico’s fresh produce exports to the U.S., hamper the competitiveness of U.S. farmers, ranchers, and other members of the food and agriculture sector. Industry Groups Raise the Alarm on U.S.-Mexico Trade Relationship Facebook Twitter SHARE By American Farm Bureau Federation – Mar 22, 2021 SHARE Previous articleHAT Market Analysis for 3/22/21 with John Zanker of Risk Management CommoditiesNext articleFFA Students Share the Story of Agriculture to Celebrate National Ag Day American Farm Bureau Federation Facebook Twitter Home Indiana Agriculture News Industry Groups Raise the Alarm on U.S.-Mexico Trade Relationship
RSF_en June 8, 2020 Find out more NepalAsia – Pacific Receive email alerts January 17, 2006 – Updated on January 20, 2016 Government plans new authority, high fees to stifle radio stations Nepalese journalists threatened, attacked and censored over Covid-19 coverage News News Follow the news on Nepal Organisation May 17, 2019 Find out more Reporters Without Borders today called on the international community, especially the United Nations, to persuade the government to rethink its plans to create a Broadcasting Authority with broad powers over radio stations, cable TV and online media, and to increase the cost of a radio broadcasting licence by at least 10 or 20 times.The proposed ordinance could have “disastrous consequences” for the development of independent radio broadcasting in Nepal, the press freedom organisation said.”After trying to silence FM radio stations by force, the authorities are now trying to suppress the right to broadcast news and information by creating an entity under its political control and by means of exorbitant licence fees,” Reporters Without Borders said.”It is deplorable that the Nepali government is attempting to introduce repressive legislation disguised as regulatory measures for the media sector just a few days before the first anniversary of the coup it staged on 1 February 2005,” the organisation added.The information ministry sent a letter to Nepalese FM radio station managers summoning them to a meeting on 19 January to discuss a proposed Broadcasting Authority and the ordinance under which the new authority will created. The letter did not however include a copy of the proposed ordinance.In an initial draft seen by some journalists, the price of a broadcasting licence has been increased 20- or 40-fold. The fee for a 50-watt transmitter goes up from 25,000 to 1 million Nepalese rupees (from 290 to 11,710 euros). For transmitters of more than 1,000 watts, the fee rises from 500,000 to 10 million rupees (from 5,850 to 117,100 euros). As the annual renewal charge is 10 per cent of the initial fee, it will also rise dramatically. Several radio station owners told Reporters Without Borders they were not sure they would be able to afford the next renewal fee.Three organisations representing radio station owners and journalists issued a warning about the “motives behind this decision to prepare a new ordinance on the part of a government which has tried by all means to control independent radio stations.” They also criticised the fact that media representatives would be in the minority in the proposed Broadcasting Authority and that its president would be a senior information ministry official. News NepalAsia – Pacific Nepal: RSF’s recommendations to amend controversial Media Council Bill Under Chinese pressure, Nepal sanctions three journalists over Dalai Lama story to go further News May 29, 2019 Find out more Help by sharing this information
WhatsApp Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–Feb 16, 2021– Centessa Pharmaceuticals (“Centessa”) launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process. The company was founded by Medicxi and raised $250 million in an oversubscribed Series A financing led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors. Additional blue-chip investors participated in the financing, including Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Wellington Management Company, BVF Partners L.P., EcoR1 Capital, Franklin Templeton, Logos Capital, Samsara BioCapital, LifeSci Venture Partners and an undisclosed U.S.-based, healthcare-focused fund. In conjunction with its launch, Centessa has completed the merger of 10 private biotech companies (“Centessa Subsidiaries”) that will each continue to develop its assets with oversight from the Centessa management team. Each Centessa Subsidiary team is asset-focused, in that it prosecutes a single program or biological pathway, with leadership provided by subject matter experts who are given a high degree of autonomy to advance each program. With a singular focus on advancing exceptional science, combined with proprietary capabilities, including structure-based drug discovery and design, the subsidiary teams enable Centessa to potentially develop and deliver impactful medicines to patients. “The vision of Centessa is to build a pharmaceutical company with a unique operational framework that aims to reduce some of the key R&D inefficiencies that classical pharmaceutical companies face because of structural constraints,” said Francesco De Rubertis, Ph.D., Co-Founder and Partner at Medicxi and Chairman of the Centessa Pharmaceuticals Board of Directors. “Our operations will be driven by an asset-centric approach, whereby each Centessa Subsidiary is solely focused on the execution of its programs with oversight from the highly experienced Centessa management team. The ambition of applying asset centricity at scale is to be able to deliver life altering medicines to patients with improved efficiency by boosting R&D productivity.” Our Approach Centessa brings together 10 companies from Medicxi’s portfolio with 15 high conviction programs led by experienced teams. Each Centessa Subsidiary is led by industry leaders and subject matter experts with deep experience directly related to key biological pathways that underpin the programs being advanced. These entrepreneurs who have catalyzed the creation of subsidiary companies will continue to advance novel science within the Centessa enterprise. The Centessa Subsidiaries are comprised of ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, Pega-One and Z Factor. The current Centessa Pharmaceuticals portfolio consists of four clinical stage programs, including two that are in late-stage clinical development, and more than 10 additional programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience and rare diseases. “With this first-of-its-kind model, we are bringing together programs with robust genetic and biological validation under one new pharmaceutical company that provides centralized resources to enable and empower asset-focused teams to advance highly impactful programs for patients,” said Saurabh Saha, M.D., Ph.D., Centessa’s Chief Executive Officer. “This approach encourages an environment where scientific teams are incentivized to maintain an unwavering focus on advancing medicines to key go/no-go inflection points based on data-driven decisions.” Centessa will have the flexibility to deploy capital by adhering to a “follow-the-data” philosophy and will support each Centessa Subsidiary with centralized capabilities that enable advancement of its respective programs. These include manufacturing, regulatory and operational support to enable and expedite scientific prosecution of programs by subsidiary teams. Each team is uniquely incentivized to expeditiously interrogate key scientific hypotheses. Moncef Slaoui, Ph.D, Chief Scientific Officer, Advisor of Centessa added, “In creating Centessa, we have strategically assembled our subsidiary portfolio to include programs with strong biological validation, mechanistic diversification, and teams with proprietary capabilities and insights. This high-quality portfolio aims to deliver enhanced diversification, reduced risk and asymmetric upside with a view to withstanding the inherent low probability of success associated with drug development.” Meet the Team The Centessa Pharmaceuticals management team consists of biotech and pharmaceutical industry leaders who oversee decisions related to capital allocation, development plans and strategic transactions in partnership with the Centessa Subsidiaries. Saurabh Saha, M.D., Ph.D ., former Senior Vice President, R&D, and Global Head of Translational Medicine at Bristol Myers Squibb, has been appointed as the company’s Chief Executive Officer and a member of the Board of Directors. In addition, Moncef Slaoui, Ph.D ., former Chief Scientific Advisor of Operation Warp Speed, former Chairman of R&D at GlaxoSmithKline, and Partner at Medicxi, has been appointed as Chief Scientific Officer, Advisor. The Centessa Board of Directors includes Francesco De Rubertis, Ph.D., Medicxi, who will serve as the company’s Chairman; Aaron Kantoff, Medicxi; Brett Zbar, M.D., General Atlantic; and Arjun Goyal, M.D., M.Phil., Vida Ventures. “We believe Centessa represents a unique opportunity in our sector,” said Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic. “The high-quality science and entrepreneurial drive within each of the Centessa Subsidiaries, combined with this deeply experienced leadership team, has the potential to bring important medicines to patients with speed and efficiency.” “Centessa’s bold vision and unique operating model are supported by compelling clinical programs, strong data and a stellar team,” said Arjun Goyal, M.D., M.Phil., Co-Founder and Managing Director at Vida Ventures. “We believe Centessa’s approach can ultimately lead to impactful medicines that will benefit patients globally.” ABOUT THE CENTESSA SUBSIDIARIES ApcinteX ApcinteX is developing SerpinPC, a specific inhibitor of the anticoagulant protease activated protein C (APC), for the treatment for hemophilia A and hemophilia B, with or without inhibitors. Capella BioScience Capella BioScience is developing CBS001, a neutralizing therapeutic monoclonal antibody to the inflammatory membrane form of LIGHT (known as TNFSF14), for the treatment of idiopathic pulmonary fibrosis. Capella BioScience is also developing CBS004, a therapeutic monoclonal antibody to blood dendritic cell antigen 2 (BDCA2), for the treatment of lupus erythematosus (systemic and cutaneous) and systemic sclerosis. Janpix Janpix is developing a novel class of selective dual-STAT3/5 small molecule monovalent degraders for the treatment of various hematological malignancies, including leukemias and lymphomas. LockBody LockBody is pioneering a platform technology to develop LockBody CD47 (LB1) and LockBody CD3 (LB2) for optimal targeting of solid tumors by the innate immune system. Morphogen-IX Morphogen-IX is developing MGX292, a protein-engineered variant of human bone morphogenetic protein-9 (BMP9), for the treatment of pulmonary arterial hypertension. Orexia Therapeutics Orexia Therapeutics is developing oral and intranasal orexin receptor agonists using structure-based drug design approaches. These agonists target the treatment of narcolepsy type 1, where they have the potential to directly address the underlying pathology of orexin neuron loss, as well as other neurological disorders characterized by excessive daytime sleepiness. Palladio Biosciences Palladio Biosciences is developing lixivaptan, an oral non-peptide, new chemical agent that works by selectively suppressing the activity of the hormone vasopressin at the V2 receptor, as a treatment for autosomal dominant polycystic kidney disease with the goal of slowing the progression of kidney function decline and avoiding the liver safety issues associated with tolvaptan. PearlRiver Bio PearlRiver Bio is developing potent and selective oral exon20 insertion mutation inhibitors intended to have minimal activity on wild-type EGFR and optimal pharmacokinetic properties, for the treatment of EGFR exon 20 insertion (with potential to target and treat Her2 exon 20 insertions) non-small cell lung cancer (NSCLC). PearlRiver Bio is also developing oral inhibitors targeting C797S-mutant EGFR and undisclosed next generation EGFR inhibitors for NSCLC. PegaOne PegaOne is developing imgatuzumab, a humanized, non-fucosylated, anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and other solid tumor indications. Z Factor Z Factor is developing ZF874, a small molecule chemical chaperone intended to rescue folding of the Z variant of alpha-1-antitrypsin, increasing serum levels of active protein and reducing accumulation in the liver, for the treatment of alpha-1-antitrypsin deficiency. ABOUT CENTESSA PHARMACEUTICALS Centessa Pharmaceuticals Limited is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams. Each program is developed by an Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team. The company is headquartered in Cambridge, Mass. For more information, visit www.centessa.com FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “estimates,” “expects,” “intends,” “anticipates,” “believes,” “may,” “should,” “will,” “plans,” “projects,” “seeks,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to expectations, plans and prospects regarding the clinical development plans and timing, clinical trial designs, clinical and therapeutic potential, and strategy for any of our programs reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of clinical trials, regulatory filings, and approvals. These forward-looking statements are based upon the current expectations and beliefs of Centessa’s management team as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Furthermore, Centessa operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on businesswire.com:https://www.businesswire.com/news/home/20210216005355/en/ CONTACT: Media: Dan Budwick, 1AB [email protected] UK/European media enquiries Optimum Strategic Communications Mary Clark, Shabnam Bashir [email protected] Swiss media enquiries VEITHing Spirit Marcus Veith [email protected] Cellphone: +41 79 20 75 111 KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH STEM CELLS GENETICS OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Centessa Pharmaceuticals Copyright Business Wire 2021. PUB: 02/16/2021 06:30 AM/DISC: 02/16/2021 06:37 AM http://www.businesswire.com/news/home/20210216005355/en Twitter Pinterest Pinterest WhatsApp Local NewsBusiness Facebook By Digital AIM Web Support – February 16, 2021 Facebook Twitter TAGS Previous articleSolarWinds Head Geek Team Adds Microsoft Data Platform Expert Kevin KlineNext articleClarkson, streaking Jazz win showdown vs Simmons, 76ers Digital AIM Web Support
News, Sport and Obituaries on Monday May 24th WhatsApp Taoiseach says country won’t pay ransom demand on HSE cyber attack AudioHomepage BannerNews The Taoiseach says the country won’t be paying a ransom demanded by those behind the HSE cyber attack.Its IT systems were targeted in the early hours of yesterday morning – and it could be a number of days before they’re restored.Thousands of appointments and procedures might have to be cancelled early next week as a result.The attack had a considerable impact on hospital services in Letterkenny University Hospital yesterday with all outpatient x-ray, CT, ultrasound and MRI appointments cancelled.The system to register for a coronavirus vaccine is back up and running – as are the Covid test result and contact tracing platforms.Taoiseach Micheál Martin says the state won’t be meeting the demands of those behind this attack:Audio Playerhttps://www.highlandradio.com/wp-content/uploads/2021/05/CyberHack10am.mp300:0000:0000:00Use Up/Down Arrow keys to increase or decrease volume. RELATED ARTICLESMORE FROM AUTHOR Facebook Twitter DL Debate – 24/05/21 Pinterest Google+ Google+ By News Highland – May 15, 2021 Previous articleCouncil carry out surfacing work on Old Laghey RoadNext articleBritish Gov. consider ban on prosecutions of soldiers that served in NI News Highland Facebook Derry draw with Pats: Higgins & Thomson Reaction WhatsApp Journey home will be easier – Paul Hegarty Pinterest FT Report: Derry City 2 St Pats 2 Harps come back to win in Waterford Twitter
Arranmore progress and potential flagged as population grows Important message for people attending LUH’s INR clinic Google+ Facebook Previous articleCensus 2016 suggests use of Irish language in Donegal is decliningNext articleHarris to discuss reopening of short stay ward with HSE News Highland RELATED ARTICLESMORE FROM AUTHOR Pinterest Facebook Concerns have been raised over the future development of three major routes in Donegal.Following presentations made by TEN-T in relation to the development of the Letterkenny to Manor route, Manor to Lifford route and the Ballybofey to Stranorlar bypass, it has been revealed that the tendering process is not scheduled to take place until 2020.Councillor Patrick McGowan, who called for the presentation says no clear commitment on the future of the projects or funding availability was given by the Trans-European Transport Network.He says there are fears Donegal will be overlooked when it comes to the allocation of funding:Audio Playerhttp://www.highlandradio.com/wp-content/uploads/2017/11/mcgowan.mp300:0000:0000:00Use Up/Down Arrow keys to increase or decrease volume. Twitter Twitter Homepage BannerNews By News Highland – November 23, 2017 WhatsApp DL Debate – 24/05/21 Disappointment after no commitment to develop three major routes in Donegal Journey home will be easier – Paul Hegarty Google+ Harps come back to win in Waterford Pinterest WhatsApp News, Sport and Obituaries on Monday May 24th
WhatsApp Twitter RELATED ARTICLESMORE FROM AUTHOR Previous articleMark English in Cork chasing World Championship timeNext articleOldtown – Rockhill Road closure deferred until November News Highland Irish Water has told Highland Radio News that it has postponed site investigations in Lough Foyle because of concerns that the works might be obstructed.They say wastewater will be treated to a very high standard in a new treatment plant at Carnagarve, and then discharged 200 metres out into Lough Foyle where it will be further diluted. It was at that point, 200 metres off shore, that the drilling work was ceased.In a statement, the utility says the drilling, while necessary to finalise the design, is not critical to the project at this stage as it prepares to submit a planning application.Irish Water say they have put the safety of their contractors’ personnel first, and postponed the investigations until a future date.They say these works will the necessary information to design the new wastewater treatment plant, sewer network and outfall pipe in a way that ensures raw sewage is no longer discharged in the Bredagh River and Lough Foyle.Irish Water say they will undertake the marine investigation surveys at a later date and hope that the community will work with them. Land based site investigation works are continuing as planned.The Campaign for a Clean Estuary, which opposes Irish Water’s plans for the new treatmentplant, claims the first indication from the local fishing fleet that it would block the work because of its impact on oyster beds was crucial in securing this decision.Irish Water say they have engaged with the Loughs Agency and the local community, and will continue to keep people updated at each stage of the project.However, Enda Craig of the Campaign for a Clean Estuary questions that assertion…………Audio Playerhttp://www.highlandradio.com/wp-content/uploads/2019/08/ecweds.mp300:0000:0000:00Use Up/Down Arrow keys to increase or decrease volume.*******************Irish Water statement in full -It is a priority of Irish Water to end the current unacceptable practice of untreated wastewater from Moville being discharged into the Bredagh River and Lough Foyle at five locations. The current discharge of untreated wastewater threatens water quality, pollutes Lough Foyle, the beaches, the coastline, the environment, and detracts from the amenity value of the river and the coastal waters around Moville and environs. Moville is one of the areas the Environmental Protection Agency (EPA) has identified as having no wastewater treatment and they have classified the Bredagh River as being ‘Seriously Polluted’.A new wastewater treatment plant and collection system is needed to end this practice. This proposed Irish Water project will treat wastewater to a high standard, and end the discharge of untreated wastewater (the equivalent of 2,800 wheelie bins per day) into Lough Foyle and the Bredagh River. The project will protect local beaches, the Bredagh River and Lough Foyle. The scheme will result in a significant environmental improvement with improved water quality in the Bredagh River, Lough Foyle and at local beaches. All of which will benefit the local community and the tourist industry.The project will consist of new sewer collection pipes, a new storm tank and pumping station at the river Row, and a new wastewater treatment plant and outfall pipe at Carngarve. The project has been designed so that in the event of very heavy rainfall storm water will collect in the storm tank and overflow via a screened outfall to the Bredagh River. The storm water tank allows solids to settle and the screen filters out any rags ensuring that overflows during storm events are mainly liquid preventing coastal sewage waste as is occurring today. The storm water tank and pumping station design also means that no untreated wastewater will ever be discharged through the new outfall at Carnagarve. Furthermore, it is proposed that wastewater will be treated to a very high standard and will be discharged 200 metres out into Lough Foyle where it will be further diluted. The proposed project will ultimately protect Lough Foyle and safeguard the environment for all to enjoy.Site investigation works are an essential stage of the project as these works will provide Irish Water with the necessary information to design the new wastewater treatment plant, sewer network and outfall pipe which will ensure raw sewage is no longer discharged in the Bredagh River and Lough Foyle.Given the location, our site investigation works must source information about the existing marine environment. This is to ensure that the future works in Moville are designed to protect the environment and enable the project to be delivered as quickly as possible. The marine site investigation works, while necessary to finalise the design, are not critical to the project at this stage as we prepare to submit a planning application. Irish Water had concerns that the site investigation works may be obstructed, and as such have put the safety of their contractors personnel first, and postponed the investigations until a future date. Irish Water will undertake the marine investigation surveys at a later date and hope that the community will work with us so that these essential investigations can be undertaken in a timely manner to ensure the water quality in Lough Foyle is improved for all to enjoy. Land based site investigation works are continuing as planned.Irish Water have engaged with the local community at every step of this project and will continue to keep them updated at each stage of the project. Similar to all other stakeholders Irish Water is keeping the Loughs Agency informed on the project and the benefits it will bring in terms of improved water quality in Lough Foyle. Google+ AudioHomepage BannerNews Facebook Pinterest WhatsApp Twitter Pinterest Google+ Loganair’s new Derry – Liverpool air service takes off from CODA FT Report: Derry City 2 St Pats 2 By News Highland – August 14, 2019 Important message for people attending LUH’s INR clinic DL Debate – 24/05/21 News, Sport and Obituaries on Monday May 24th Irish Water postponed drilling because of obstruction concerns Arranmore progress and potential flagged as population grows Facebook